Third Wave Technologies wants its Invader technology to be as ubiquitous as PCR. Since a deal with potential buyer Applera fell through two years ago, the company has begun several high-profile collaborations, including one with the Japanese SNP initiative, which now accounts for 50% of revenues. Its efforts appear to be paying off, but the company is fighting an uphill battle in an intensely competitive field.
by Wendy Diller
With some fanfare, PE Biosystems Inc., a business unit of PE Corp., agreed in January 2000 to buy Third Wave...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.
